Merck & Co Stock

Merck & Co EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Merck & Co (MRK) as of Jul 30, 2026 is 12.83. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 14.90 — a change of -13.90% (lower).

EV/EBIT

12.83

YoY

-13.90%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Merck & Co is 2026 12.83 . EV/EBIT (Enterprise Value to EBIT) of Merck & Co was 2025 14.90 . It decreases by -13.90% lower compared to the previous year.

The Merck & Co EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
28.02 base
Jan 1, 2020
31.37 base
Jan 1, 2021
13.91 base
Jan 1, 2022
15.46 base
Jan 1, 2023
94.26 base
Jan 1, 2024
12.50 base
Jan 1, 2025
11.15 base
Jan 1, 2026 (e)
13.72 base
YEARPRICE-TO-EBIT
2026 est 13.72
2025 11.15
2024 12.50
2023 94.26
2022 15.46
2021 13.91
2020 31.37
2019 28.02
2018 21.50
2017 21.45
2016 28.36
2015 18.79
2014 23.35
2013 18.44
2012 12.16
2011 12.30
2010 31.57
2009 18.29
2008 10.15
2007 21.51
2006 24.55
Access this data via the Eulerpool API
Get Free API Key

Merck & Co Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Merck & Co's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Merck & Co's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Merck & Co's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Merck & Co grows earnings faster than its peers.

Merck & Co Stock analysis

What does Merck & Co do? The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards. Merck & Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Merck & Co stock

EV/EBIT (Enterprise Value to EBIT) of Merck & Co is 12.83 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Merck & Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Merck & Co